Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Neisseria gonorrhoeae

5

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

US Previously Marketed

2

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

2

2017

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Gonorrhea

5

Community-acquired bacterial pneumonia

3

Acute bacterial skin and skin structure infection

2

Ocular fungal infections

2

Pregnancy

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

British Drug Houses

2

Wakunaga Pharmaceutical

2

Optimer Pharmaceuticals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

NCI_THESAURUS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS

1

QUINOLONE ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Fluoroquinolones

1

Macrolides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DELAFLOXACIN

6315412YVF

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Klebsiella pneumoniae

Staphylococcus aureus

Haemophilus influenzae

Moraxella catarrhalis

Neisseria gonorrhoeae

Conditions:

Community-acquired bacterial pneumonia

Acute bacterial skin and skin structure infection

Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a ...

fluoroquinolone antibiotic, is currently being developed by Melinta Therapeutics. It is a novel investigational fluoroquinolone in development for the treatment of uncomplicated gonorrhea, and acute bacterial skin and skin structure infections. Delafloxacin shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. Delafloxacin is a dual-targeting fluoroquinolone, capable of forming cleavable complexes with DNA and topoisomerase IV or DNA gyrase and of inhibiting the activity of these enzymes in both Gram-positive and Gram-negative bacteria. On Oct 24, 2016, Melinta Therapeutics Submitted Baxdela New Drug Application for hospital-treated skin infections.

PHENYLMERCURIC ACETATE

OSX88361UX

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Neisseria gonorrhoeae

platelet aggregation

Aspergillus sp.

Conditions:

Ocular fungal infections

Phenylmercuric ammonium acetate is a fungicide and bactericide. It is used for the seed treatment.

SOLITHROMYCIN

9U1ETH79CK

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

50S subunit assembly, S. pneumoniae

Streptococcus pneumoniae

Staphylococcus aureus

Neisseria gonorrhoeae

Conditions:

Community-acquired bacterial pneumonia

Solithromycin is a highly potent next-generation macrolide, the first fluoroketolide, which has potent activity against most macrolide-resistant strains. In vitro and in vivo studies have shown potent activity against S. pneumoniae as well as an exte...

nded spectrum of activity against CA-MRSA, enterococci, Mycobacterium avium and in animal models of malaria. It is also active against atypical bacteria, such as Legionella, Chlamydophila, Chlamydia, Mycoplasmaand Ureaplasma and against gonococci and other organisms that cause genitourinary tract infections. It is 8-16 times more potent than azithromycin and is active against azithromycin-resistant strains. Its activity against resistant strains is driven by its ability to bind to three sites on the bacterial ribosome, compared to one or two for current macrolides. It binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis. The binding to three ribosomal sites is expected to limit resistance development. On July 2016 Cempra Announces FDA Acceptance of IV and oral formulations of Solithera (solithromycin) New Drug Applications for in the treatment of community-acquired bacterial pneumonia.

DELAFLOXACIN MEGLUMINE

N7V53U4U4T

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Klebsiella pneumoniae

Staphylococcus aureus

Haemophilus influenzae

Moraxella catarrhalis

Neisseria gonorrhoeae

Conditions:

Community-acquired bacterial pneumonia

Acute bacterial skin and skin structure infection

Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a ...

fluoroquinolone antibiotic, is currently being developed by Melinta Therapeutics. It is a novel investigational fluoroquinolone in development for the treatment of uncomplicated gonorrhea, and acute bacterial skin and skin structure infections. Delafloxacin shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. Delafloxacin is a dual-targeting fluoroquinolone, capable of forming cleavable complexes with DNA and topoisomerase IV or DNA gyrase and of inhibiting the activity of these enzymes in both Gram-positive and Gram-negative bacteria. On Oct 24, 2016, Melinta Therapeutics Submitted Baxdela New Drug Application for hospital-treated skin infections.

PHENYLMERCURIC AMMONIUM ACETATE

272963SQX8

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Neisseria gonorrhoeae

platelet aggregation

Aspergillus sp.

Conditions:

Ocular fungal infections

Phenylmercuric ammonium acetate is a fungicide and bactericide. It is used for the seed treatment.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1